Bradley Dixon, MD
Enriched profileAssociate Professor and Head, Section of Nephrology · University of Colorado Denver School of Medicine
Bradley Dixon is Associate Professor and Head, Section of Nephrology at University of Colorado Denver School of Medicine. OpenAlex indexes 192 publications with 3,127 citations (h-index 28); ClinicalTrials.gov lists 4 registered studies with this person as an investigator.
Data verified 23 Oct 2026
Overview
Updated 24 Oct 2026
Bradley P. Dixon, MD, is Associate Professor and Head, Section of Nephrology at University of Colorado Denver School of Medicine. The public record shows 192 publications with 3,127 citations (h-index 28), centered on Complement system in diseases, Renal Diseases and Glomerulopathies, Renal Transplantation Outcomes and Treatments. It also documents an investigator role on 4 registered clinical trials, industry payments reported by 6 companies, 2 NIH-funded awards (1987–1990).
- Most recent indexed publication: 2026 · Clinical journal of the American Society of Nephrology
- Top research focus: Complement system in diseases
- 4 registered trials on ClinicalTrials.gov
- Open Payments reporting from 6 companies
Generated from the cited public record · current as of 24 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 12 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 48.
Clinical & industry
trials, payments and federal fundingContact
No public contact details on file. This person's NPPES record doesn't include a practice address or telephone number. Why? →
Clinical trials
Updated 24 Oct 2026
Listed as an investigator on 4 registered studies on ClinicalTrials.gov. The most recent:
- Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN
Sponsor: Novartis Pharmaceuticals
- Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN
Sponsor: Novartis Pharmaceuticals
- Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Sponsor: Novartis Pharmaceuticals
Industry payments
Updated 24 Oct 2026
6 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Alexion Pharmaceuticals, Inc.Program year202521 payments$47,136openpaymentsdata.cms.gov ↗
- Apellis Pharmaceuticals, Inc.Program year20254 payments
- Novartis Pharmaceuticals CorporationProgram year20253 payments
NIH funding
Updated 24 Oct 2026
2 NIH research awards on record, funded 1987–1990 per NIH RePORTER. The latest:
- DNA Damage and Response in the Bladder Microenvironment.
Cincinnati Childrens Hosp Med Ctr
FY2014$147,876K08DK081737 - DNA Damage and Response in the Bladder Microenvironment.
Cincinnati Childrens Hosp Med Ctr
FY2013$147,876K08DK081737 - DNA Damage and Response in the Bladder Microenvironment.
Cincinnati Childrens Hosp Med Ctr
FY2012$150,490K08DK081737
Congress activity
Updated 24 Oct 2026
2 congress contributions (2019–2021) across ASH per OpenAlex. The most recent:
- Two-Year Efficacy and Safety of Ravulizumab in Adults and Children with Atypical Hemolytic Uremic Syndrome (aHUS): Analysis of Two Phase 3 Studies
ASH Annual Meeting
ASH2021Presenting author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 24 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Natural History of C3 Glomerulopathy and Immune Complex-Associated Membranoproliferative Glomerulonephritis in Children.
Clinical journal of the American Society of Nephrology
Article2026 - Pegcetacoplan Versus Iptacopan for the Treatment of Patients with C3 Glomerulopathy: Indirect Treatment Comparisons.
Advances in therapy
Clinical Trial2026 - Pegcetacoplan for Adolescents with C3 Glomerulopathy or Primary Immune Complex Membranoproliferative GN: Phase 3 VALIANT Subgroup Analysis.
Clinical journal of the American Society of Nephrology
Clinical Trial2026 - Biomarkers in the Management of Complement-Mediated Kidney Diseases in the Era of Complement Therapeutics.
Clinical journal of the American Society of Nephrology
Review2026 - Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN.
The New England journal of medicine
Clinical Trial2025
Most-cited works
by citation count (OpenAlex)- 01
- 02
- 03
- 04
- 05Tuberous Sclerosis Complex Renal DiseaseArticle161 citations2010
Network
Updated 24 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 24 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Other
childrenscolorado.org/doctors-and-departments/physicians/d/bradley-dixon
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →childrenscolorado.org ↗
Mentions by others
where others cite or feature them- Other
medschool.cuanschutz.edu/pediatrics/sections/nephrology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medschool.cuanschutz.edu ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 24 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →childrenscolorado.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →childrenscolorado.org ↗
Editorial & leadership roles
journal and society appointments- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →library.annanurse.org ↗
Secondary affiliations
appointments beyond the home institution- Children's Hospital Colorado
Department of Pediatric Nephrology (Anschutz Medical Campus, Aurora)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →childrenscolorado.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Toni Choueiri, MD
Dana-Farber Cancer Institute
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Fred Saad, MD
Centre hospitalier de l'Université de Montréal (CHUM)